McGee David H, Holt William F, Kastner Philip R, Rice Rebecca L
Alcon Research, Ltd., Fort Worth, Texas 76134-2099, USA.
Surv Ophthalmol. 2005 Nov;50 Suppl 1:S46-54. doi: 10.1016/j.survophthal.2005.05.003.
Topical treatment of ocular bacterial infection is practiced widely, and the choice of the antibacterial agent depends on the nature of the infection, including the susceptibility of the organism, the tissue affected, and the safety profile of the agent. Moxifloxacin is a fourth-generation fluoroquinolone approved for ophthalmic use as moxifloxacin ophthalmic solution 0.5% (VIGAMOX, Alcon, Fort Worth, TX). Moxifloxacin ophthalmic solution 0.5% is self-preserved at a near-neutral pH of 6.8. In treating ocular infection, the three important aspects of therapeutic control are potency, penetration of the drug to the target site, and safety of the drug and the drug product. Moxifloxacin ophthalmic solution 0.5% provides antibacterial potency and high penetration of target ocular tissues. The ocular and systemic safety profile of moxifloxacin compares favorably with those of other fluoroquinolone antimicrobial agents, with a low risk of recognized quinolone-related toxicity. In vitro studies of fluoroquinolones with human or rabbit corneal epithelial cells or keratocytes suggest that moxifloxacin is similar in cytotoxicity potential to other drugs of this family. Specialized in vivo corneal wound-healing studies draw little distinction between moxifloxacin-treated eyes and those treated with other fluoroquinolones. Repeated-dose topical ocular studies in rabbits and monkeys, with high concentrations (up to 3%) of moxifloxacin and at treatment durations and regimens well in excess of label-prescribed use, demonstrated a high safety margin for ocular and extraocular tissues. Cornea, the tissue with highest exposure, was found to be unaffected by these high exposures, with slit-lamp biomicroscopy, corneal thickness measurement, intraocular pressure, and specular microscopy of the corneal endothelium (monkeys only), and histologic evaluation showing no effects, as compared with controls. Moxifloxacin ophthalmic solution 0.5% affords superior efficacy and ocular tissue penetration, with a favorable safety profile.
眼部细菌感染的局部治疗应用广泛,抗菌药物的选择取决于感染的性质,包括病原体的敏感性、受影响的组织以及药物的安全性。莫西沙星是一种第四代氟喹诺酮类药物,以0.5%莫西沙星滴眼液(VIGAMOX,爱尔康公司,得克萨斯州沃思堡)获批用于眼科。0.5%莫西沙星滴眼液在接近中性的pH值6.8时可自我保存。在治疗眼部感染时,治疗控制的三个重要方面是效力、药物对靶部位的渗透以及药物和药品的安全性。0.5%莫西沙星滴眼液具有抗菌效力且能高度渗透到眼部靶组织。莫西沙星的眼部和全身安全性与其他氟喹诺酮类抗菌药物相比具有优势,喹诺酮相关毒性的风险较低。对人或兔角膜上皮细胞或角膜细胞进行的氟喹诺酮类药物体外研究表明,莫西沙星在细胞毒性潜力方面与该类其他药物相似。专门的体内角膜伤口愈合研究显示,莫西沙星治疗的眼睛与用其他氟喹诺酮类药物治疗的眼睛之间没有明显差异。在兔子和猴子身上进行的重复剂量局部眼部研究中,使用高浓度(高达3%)的莫西沙星,治疗持续时间和方案远远超过标签规定的使用范围,结果表明眼部和眼外组织具有很高的安全系数。通过裂隙灯生物显微镜检查、角膜厚度测量、眼压测量以及角膜内皮的镜面显微镜检查(仅针对猴子)发现,暴露程度最高的组织角膜并未受到这些高暴露的影响,与对照组相比,组织学评估也未显示出任何影响。0.5%莫西沙星滴眼液具有卓越的疗效和眼部组织渗透性,安全性良好。